Daiichi Sankyo has partnered with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology.

Kailera's IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials.

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

Aligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection.

Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.

The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial.

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.

Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.

An analyst noted that this uptick may be a case of “frontloading”, meaning the EU’s 2026 pharma export growth outlook may not be as strong.

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.

Travere Therapeutics has received FDA approval for Filspari to reduce proteinuria in patients aged eight years and over with FSGS without nephrotic syndrome.

Eli Lilly and Eisai have backed their Alzheimer’s disease drugs despite research finding the mechanism of action may be less clinically meaningful than suggested. A review by Cochrane found that the ...